Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490903 | 0.79 | ANPEP (0.31) | — | |
| SCHEMBL6480677 | 0.73 | CYP19A1 (0.33) | CYP19A1IDO1GBA1 | |
| SCHEMBL29447948 | 0.73 | IDO1 (0.47) | CYP19A1IDO1GBA1DRD3 | |
| SCHEMBL835059 | 0.73 | IDO1 (0.47) | CYP19A1IDO1GBA1DRD3 | |
| SCHEMBL6480714 | 0.72 | DRD3 (0.30) | DRD3 | |
| SCHEMBL6480327 | 0.70 | FABP7 (0.35) | IDO1 | |
| SCHEMBL15701675 | 0.65 | CYP19A1 (0.54) | CYP19A1GBA1 | |
| SCHEMBL6570371 | 0.65 | CYP19A1 (0.54) | CYP19A1GBA1 | |
| SCHEMBL1689627 | 0.65 | CYP19A1 (0.54) | CYP19A1GBA1 | |
| SCHEMBL7214515 | 0.62 | CA1 (0.43) | CYP19A1IDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 | CYP19A1 1550/4885IDO1 3806/4885GBA1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.